EZH2表达与老年直肠癌患者预后的相关性研究  

Prognostic significance of EZH2 expression in elderly patients with rectal cancer and its possible mechanism

作　　者：沈海峰[1] 杨广 王勇[1] 范亚召 SHEN Hai-feng;YANG Guang;WANG Yong;FAN Ya-zhao(Department of Anorectal Surgery, Fourth People＇s Hospital of HENG Shui, Hebei Province（HENGshui 253000, China)

机构地区：[1]河北省衡水市第四人民医院肛肠外科,河北衡水253000

出　　处：《中国现代普通外科进展》2018年第2期98-101,共4页Chinese Journal of Current Advances in General Surgery

摘　　要：目的:探讨老年直肠癌(CRC)患者EZH2表达水平及与预后的关系。方法:收集2010年1~6月在本院接受手术治疗的36例老年CRC患者的病例资料。患者年龄65~83岁,平均年龄71.26±9.68岁。检测患者癌组织及癌旁组织中EZH2表达水平,分析癌组织中EZH2阳性表达的相关因素;根据癌组织中EZH2表达水平将患者分为高表达组与低表达组,随访1年评估患者预后,并分析与EZH2表达水平的相关性;随访5年对比两组患者5年无病情进展生存率及总生存率。结果:36例老年CRC患者癌组织中EZH2表达阳性率(69.44%)显著高于癌旁组织(38.89%,P<0.01)。EZH2阳性表达率与CRC患者年龄、病理分型、浸润程度、淋巴转移相关(P<0.05);Logistic回归分析结果显示EZH2阳性表达是CRC淋巴转移的独立危险因素。随访1年EZH2低表达组QLQ-30生活质量评分显著高于EZH2高表达组(P<0.01);EZH2表达水平与QLQ-30生活质量评分呈负相关性(r=-0.573,P<0.01)。EZH2低表达组患者5年无病情进展生存率为86.67%,5年总生存率为93.33%;EZH2高表达组患者5年无病情进展生存率为52.38%,5年总生存率为61.90%;EZH2低表达组5年无病情进展生存率及5年总生存率均明显优于EZH2高表达组(P<0.05)。结论:EZH2高表达与直肠癌病情进展密切相关,可作为老年患者预后生存质量、无进展生存时间及总生存时间的一项重要预测指标。Objective： To investigate the relationship between the expression of EZH2 and the prognosis of elderly patients with rectal cancer and the mechanism of EZH2 in the progression of rectal cancer. Methods： 36 cases of elderly patients with rectal cancer who underwent surgery in our hospital from January to June 2010 were included in this study. The expression of EZH2 in col- orectal cancer tissues and adjacent tissues was analyzed and the differences were analyzed. All the patients were divided into positive and negative groups according to the expression level of EZH2. The correlation factors and risk factors of EZH2 expression were analyzed. All patients were followed up for 1 year to assess the quality of life of patients with prognosis and to analyze the correlation with the expression of EZH2; 5-year follow-up of patients in both groups compared to 5-year pro- gression-free survival rate of progression-free survival And overall survival（PFS） and overall survival （OS） survival curves were recorded. Results： The positive rate of EZH2 was 69.44% in CRC and 38.89% in cancerous tissues, and the positive rate of EZH2 in cancer tissues was significantly higher than that in adjacent tissues （P〈0.01）. Age, pathologic type, The positive rate of EZH2 expression in lymph node metastasis group was significantly higher than that in lymph node metastasis group （P〈0.05）. Logistic regression analysis showed that EZH2 expression was an independent risk factor of CRC lymph node metastasis. The QLQ-30 quality of life score was significantly higher in EZH2 low-expression group than that in EZH2 high-expression group （P〈0.01）. The expression level of EZH2 was negatively correlated with QLQ-30 quality of life score （r=-0.573, P〈0.01）. The 5-year progression-free survival rate of the 5-year EZH2 low-expression group was 86.67% and the 5-year overall survival rate was 93.33%. The 5-year progression-free survival rate was 52.38% 61.90%. The 5-year progression-free survival rate and 5-year overall su

关 键 词：直肠癌 EZH2 预后 老年 

分 类 号：R735.37[医药卫生—肿瘤]